NASDAQ · CRBP
Corbus Pharmaceuticals Holdings, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CRBP: Nov 11, 2026
Corbus Pharmaceuticals Holdings, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.45. The reported EPS for the same quarter last year was $-1.9.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.45 | $-0.95 | $-1.91 | 5 |
| Dec 2026 | $-1.46 | $-0.99 | $-1.74 | 5 |
| Mar 2027 | $-1.34 | $-1.13 | $-1.73 | 3 |
| Jun 2027 | $-1.38 | $-1.15 | $-1.71 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · MarketBeat · RTTNews · Fintel- Zacks · Sep 17, 9:00 AM EDTIs CRBP a Good Cannabis Investment After Positive Obesity Study Data?Corbus Pharmaceuticals' positive obesity data boosts its cannabinoid strategy, while CRB-701 and cash needs add key context for investors.
- MarketBeat · Sep 15, 4:02 AM EDTCorbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity StudyCorbus Pharmaceuticals stock: An explosive 342% YTD surgeCorbus Pharmaceuticals (NASDAQ:CRBP) reported top-line results from CANYON-1, a Phase 1b trial evaluating CRB-913, an oral, peripherally restricted CB1 inverse agonist for obesity. The 12-week, placebo-controlled study enro
- RTTNews · Sep 14, 7:45 AM EDTCorbus Announces Positive Phase 1b Weight-Loss Data Showing For Oral Candidate CRB-913; Stock Up(RTTNews) – Corbus Pharmaceuticals Holdings, Inc. (CRBP), announced positive topline results from its CANYON-1 Phase 1b study evaluating daily oral CRB-913 for obesity, with the 60 mg dose achieving statistically significant and clinically meaningful mean weight loss of 5% at 12
- RTTNews · Aug 5, 7:03 AM EDTCorbus Completes Final Patient Visit In Phase 1b CRB-913 Trial For Obesity(RTTNews) – Corbus Pharmaceuticals Holdings, Inc. (CRBP), a clinical-stage biotech company focused on developing therapies for oncology and obesity, announced that the last patient has completed the last clinical visit in the Phase 1b CANYON-1 trial evaluating CRB-913 in patients
- RTTNews · Jul 28, 10:21 AM EDTCorbus Says FDA Cleared Registrational TEMPO-1 Study Of CRB-701 For 2L-Oropharyngeal Cancer(RTTNews) – Corbus Pharmaceuticals Holdings, Inc. (CRBP), a clinical-stage company focused on developing therapies for oncology and obesity, on Tuesday announced that the U.S. FDA has cleared the initiation of TEMPO-1 registrational study evaluating CRB-701 for the treatment of s
- RTTNews · Jul 6, 8:40 AM EDTCorbus Pharmaceuticals Appoints Leonardo Viana Nicacio As CMO(RTTNews) – Corbus Pharmaceuticals Holdings, Inc. (CRBP), a company focused on oncology and obesity, said on Monday that it has appointed Leonardo Viana Nicacio as Chief Medical Officer.
- MarketBeat · Jun 9, 5:02 AM EDTCorbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts NearCorbus Pharmaceuticals stock: An explosive 342% YTD surgeCorbus Pharmaceuticals (NASDAQ:CRBP) Chief Executive Yuval Cohen outlined the company’s near-term clinical readout schedule and development plans for its two lead drug candidates during a Jefferies fireside chat hosted by b
- MarketBeat · Jun 1, 10:04 AM EDTCorbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 StudyCorbus Pharmaceuticals stock: An explosive 342% YTD surge Corbus Pharmaceuticals (NASDAQ:CRBP) executives and oncology specialists used an ASCO-linked discussion to outline the rationale for focusing the company’s CRB-701 program on recurrent or metastatic oropharyngeal head
- MarketBeat · May 22, 3:04 AM EDTCorbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity ReadoutCorbus Pharmaceuticals stock: An explosive 342% YTD surgeCorbus Pharmaceuticals (NASDAQ:CRBP) Chief Executive Officer Yuval Cohen said investors should expect more mature clinical updates for CRB-701 at the upcoming ASCO meeting, including the first durability and progression-fre
- RTTNews · May 21, 10:34 PM EDTBiotech Stock Gainers: CODX Extends Rally, SBFM Surges, GOVX Ebola Strategy, RGNX Awaits Catalysts(RTTNews) – Today's gainers include CODX, which rallied for the third straight day; Akari, on breakthrough clinical data in pancreatic cancer; Sunshine, following regulatory approval for its generic Amoxicillin; GOVX, amid Ebola concerns; and RGNX, on upcoming clinical trial mile
- Fintel · Apr 29, 8:04 PM EDTGuggenheim Initiates Coverage of Corbus Pharmaceuticals Holdings (CRBP) with Buy RecommendationFintel reports that on April 29, 2026, Guggenheim initiated coverage of Corbus Pharmaceuticals Holdings (NasdaqCM:CRBP) with a Buy recommendation. Analyst Price Forecast Suggests 326.72% Upside
- RTTNews · Apr 7, 9:14 AM EDTCorbus Pharma Aligns With FDA On Registration Path For CRB-701 In HNSCC And Cervical Cancer(RTTNews) – Corbus Pharmaceuticals Holdings, Inc. (CRBP), a clinical-stage company, Tuesday announced that it broadly aligned with the FDA on the registration path for CRB-701, a highly stable Nectin-4 targeting ADC, in head and neck squamous cell carcinoma (HNSCC) and cervical c
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Corbus Pharmaceuticals Holdings, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.